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The development of Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition, and International Classi-
fication of Diseases, Eleventh Edition, deserves a signifi-
cant conceptual step forward. There is a clear need to
improve and refine the current diagnostic criteria, but
also to introduce dimensions, perhaps not as an alternative
but rather as a useful complement to categorical diagnosis.
Laboratory, family, and treatment response data should
alsobesystematicallyincludedinthediagnosticassessment
when available. We have critically reviewed the content,
concurrent, discriminant, and predictive validity of bipolar
disorder, and to overcome the validity problems of the
current classifications of mental disorders, we propose a
modular system which may integrate categorical and
dimensional issues, laboratory data, associated nonpsychi-
atric medical conditions, psychological assessment, and so-
cial issues in a comprehensive and nevertheless practical
approach.
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Introduction
Challenging the Kraepelinian Dichotomy: Categorical
Versus Dimensional Approaches
Modern classifications of mental disorders assume a cat-
egorical model which may be helpful in terms of reliabil-
ity and communication among clinicians and researchers
butwhichraiseseriousconcernsaboutdiagnosticvalidity
and boundaries between entities. The concept of psycho-
sis and the entities that may be grouped under that um-
brella may themselves be questionable. Moreover, the
classification of psychoses has been a topic of vigorous
debate ever since its conception with the formulation
of the disease concepts of dementia praecox and
manic-depressive insanity by Emil Kraepelin in 1896
and their subsequent codification into the nosologic en-
tities of schizophrenia and bipolar illness.
1,2 There has
been an intensive debate on whether these 2 conditions
are distinct or related and potentially overlapping ill-
nesses. Categorical approaches, as those from Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edi-
tion,TextRevision(DSM-IV-TR),andInternationalClas-
sification of Diseases, Tenth Edition (ICD-10), may be
useful in clinical practice but leave many patients out
of the diagnostic system (the disappointing subcategory
of‘‘not-otherwise-specified’’) andprovideaverypoorso-
lution to the problem of symptomatic overlap, either by
causing huge comorbidity or by creating intermediate
categories such as ‘‘schizoaffective disorder.’’ From the
research point-of-view, dimensional approaches seem
much more useful, but are clearly less practical under
routine clinical conditions.
The Validity of Psychiatric Diagnosis
In the absence of an etiologically based classification,
attempts have been made to build a diagnostic system
of mental conditions that could be used across different
cultures. As formulated by Robins and Guze,
3 introduc-
ing a biomedical approach to psychiatric nosology that
has been extremely successful in the last 3 decades, the
validity of psychiatric diagnosis may rely on several
domains: (1) content validity, involving basically symp-
toms and clinical diagnostic criteria; (2) concurrent
validity, defined by neurobiological correlates such as
laboratoryfindings,neuroimagingandneuropsychology,
genetics, family studies, and perhaps also treatment re-
sponse; (3) predictive validity, which has mainly to do
with diagnostic stability over time; and (4) discriminant
validity,whichinvolvesdelimitationfromotherdisorders.
This formulation, directly inherited from Sydenham’s ap-
proach to general medicine, had the virtue of approach-
ing psychiatry to other medical specialities, to counteract
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886the predominant Freudian theories that were leaving
psychiatry orphan of any operational taxonomy, and
to become the foundation of the first modern classifica-
tionofpsychiatricdisordersbasedonoperationalizedcri-
teria,
4 and the grounds for the most successful one, the
DSM-III.
5 Further developments were the DSM-III-R,
the DSM-IV, and DSM-IV-TR. In 1992, The World
Health Organization applied the same approach to their
latter version of the International Classification of Dis-
eases, the ICD-10.
6
The Validity of Bipolar Disorder as a Diagnostic
Category
Content Validity Problems of Current Deﬁnitions of
Bipolar Disorder
The concept of bipolar disorder involves the current or
past occurrence of at least one episode of mania or hypo-
mania or a mixed episode, which is usually, but not nec-
essarily, preceded or followed by a depressive episode,
cyclic changes between mood states, and eventually psy-
chotic symptoms, which are assumed to be a marker of
the severity of the episode. By excluding psychotic symp-
toms from the definition, leaving them as mere correlate
of impairment or severity (criterion D), the DSMs have
indirectly reinforced the (wrong) idea that psychotic
symptoms are a core feature of schizophrenia but not
bipolar disorder. Furthermore, they have taken little ad-
vantage of the potential value of characterizing psychotic
features (ie, mood congruent vs mood incongruent) for
discriminant validity vs schizophrenia.
Moreover, the definition of major depression in bipo-
lar disorder in the DSMs does not make any difference
with unipolar depression. Nevertheless, the DSM ac-
knowledges the bipolar/unipolar dichotomy as opposed
to the Kraepelinian concept of manic-depressive illness,
whichis stilladvocatedbysomeauthors.
7Thiscarriesthe
problemthat the diagnosisofbipolardepressioncan only
be made after a manic, hypomanic, or mixed episode has
occurred. The system is, thus, assuming some loss of pre-
dictive validity in unipolar depression and increasing the
heterogeneity of the concept of major depression, which
may be too broad. Conversely, the concept of mixed epi-
sodes is verynarrowly defined as the concurrence of a full
manic and depressive episode, leaving behind many po-
tentially useful concepts such as mixed hypomania
8,9 and
excludingthepossibilitythatbipolarIIpatientsmayhave
mixed episodes. The definition of mixed states underlines
once again the difficulties of converting dimensional con-
cepts into diagnostic categories.
ICD-10 was to ICD-9 what DSM-III was to DSM-II:
a major switch from a pure classification code towards
a novel classification with operational diagnostic criteria;
in some way, it was born as a ‘‘global’’ alternative to
DSM-III. As far as bipolar disorder is concerned, the
most relevant difference between the 2 systems is that
in ICD-10 episodes are also diagnosis and that hypoma-
nia is seen as mild form of mania in the latter (1 week
duration, social impairment needed); to differentiate
the concept between affective and nonaffective psycho-
ses,the ‘‘prominence’’ ofpsychoticvs affectivesymptoms
is claimed, without any clear definition of what promi-
nence means.
Concurrent Validity: The Need of Embedding Biological
Markers Into the Diagnostic System
To a great extent, the social success of Medicine over the
last 100 years has depended on laboratory findings and
the support of technology to clinician’s skills. In psychi-
atry, practically no tools other than psychopathological
assessment are still available as routine diagnostic tests,
and in fact, this is one of the main reasons why a reliable,
clinically based diagnostic system is still necessary, but
there has been substantial progress in using biological
findings as diagnostic validators. Hence, the list of find-
ings in bipolar disorder with significantly better sensitiv-
ity and specificity than chance is quite long, but none of
them has a clear use in clinical practice. However, the
coming diagnostic systems cannot ignore anymore this
long list of validators, including laboratory, neuroimag-
ing, neuropsychology, genetic, and therapeutic data.
Therefore, it may be the time to design a ‘‘psychiatric
toolbox,’’ including genotyping, neurophysiologic, neu-
roimaging, and neuropsychological tests, which may
help to identify biomarkers that are persistent, rather
than trait dependent, to improve the validity of the
psychiatric classification and its pathophysiological
grounds. Clearly, more research is urgently needed in or-
der to be able, as soon as possible, to add laboratory
measures to the classification system.
Although concurrent validity can be narrowly defined
to include only ‘‘hard’’ laboratory data, we think that
family studies, which were defined separately by Robins
and Guze,
3 and neuropsychological findings can be in-
cluded in this concept too. There is no question that
the exclusion of family data from the diagnostic systems
was not decided merely on sensitivity/specificity ratio; in
fact, family history may be much more useful for certain
conditions, including bipolar disorder, than some of the
official criteria in the DSM-IV list. It was rather a ‘‘phil-
osophical’’ decision, which should be revised promptly.
Assuming that there is no single symptom which is exclu-
sive of bipolar disorder or schizophrenia, including the
Schneiderian first-rank symptoms,
10 the utility of family
history is probably higher than that of many of the cur-
rent criteria.
With regards to genetics, current knowledge supports
that there is indeed some overlap in the genes that pre-
dispose to bipolar disorder and schizophrenia. One
gene, (G72), has been repeatedly implicated as an over-
lap gene,
11 whereas DISC1, COMT, BDNF, and others
may constitute additional shared susceptibility genes.
12
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nonpsychotic bipolar disorder or cyclothymia, on the
one hand, and negative symptoms or the deficit syn-
drome, on the other—could turn out to have their own
unique genetic determinants.
13 If genotypes are to be
the anchor points of a clinically useful system of classi-
fication, they must ultimately be shown to inform prog-
nosis, treatment, and prevention. No gene variants have
yet met these tests in bipolar disorder or schizophrenia
but may hopefully be used as diagnostic validators con-
currently with clinical criteria in the near future.
Imaging data examining volume loss in brain struc-
tures are also consistent with some overlap between diag-
nostic categories within the spectrum of psychoses.
Genetic risk for schizophrenia may be associated with
volume loss in gray matter in left frontal-striatum-
thalamic and temporal areas, whereas the genetic risk
for bipolar disorder may be associated with volume
loss in gray matter in the right anterior cingulate cortex
and in the ventral striatum. However, genetic risk for
both conditions is also associated with brain changes
as volume loss in white matter in frontal and temporo-
parietal areas.
14 The most prominent brain abnormality
in bipolar disorder is enlargement of the amygdala.
15 In
addition, there might be structural changes in other lim-
bic structures and hippocampus, the frontal lobe, cere-
bellum, and pituitary.
16 Again, none of these findings
is specific enoughto be usedas a diagnostic test in clinical
practice, but the consistency of the findings suggests that
they do have some diagnostic validity. As an example of
the progress made by neuroimaging studies in particular
in providing data to support the diagnostic validity of bi-
polar disorder, we discuss in the companion article to this
article recent promising findings from structural and
functional neuroimaging studies that suggest persistent
regional neural abnormalities in bipolar disorder.
Neuropsychological tests have shown consistently that
bothschizophreniaandbipolardisorderareassociatedto
significant cognitive problems, which may be more in-
tense in the former.
17,18 Differences may involve atten-
tion, verbal memory, and executive function,
19 and
particularly premorbid intelligence.
20–22 None of these
issues is currently included in the classificatory system.
Some of the reasons that are often given to exclude
this kind of information from the diagnostic criteria
are that their specificity is not very high and they are
not available to the majority of clinicians. However,
this could be easily solved by devoting a supplementary
axistobiologicalandneuropsychologicalmarkers,which
could, initially, work just as a source of complementary
or supportive information which might also help to stim-
ulate further research.
Indeed, there is a long-lasting tradition in psychiatry to
try to use laboratory test to verify clinical impressions.
The initial expectations related to rapid eye movement
(REM) latency tests and dexamethasone suppression
tests were not accomplished because they would not be
able to replace clinical judgment, and actually their sen-
sitivity/specificity ratio was poorer than that of most
clinical criteria used in the classificatory system. Subse-
quently, many other neurophysiological and biochemical
tests have been developed, showing consistently that bi-
polar disorder has significant neurobiological correlates
that may enhance concurrent validity, as suggested in our
proposal for a modular classification below.
Biomarkers may not only increase concurrent validity
but also discriminant validity. The same applies to treat-
ment response. In the case of bipolar disorder, treatment
response may be particularly helpful as far as lithium
and perhaps other so-called mood stabilizers are con-
cerned: Lithium has been reported to be effective in ma-
nia but not in schizophrenia
23 and is likely to be more
effective in bipolar depression than unipolar depres-
sion.
24 Lamotrigine may also be more helpful for bipolar
depressionthanunipolardepression.
25Theremaybeafa-
milial disposition to lithium response.
26 Bipolar patients
are also more likely to switch to mania when treated
with antidepressants than unipolar patients.
27
Discriminant Validity of Bipolar Disorder: Delimitation
From Other Disorders
In the absence of an etiological classification, discrimi-
nant validity is far from ideal in any classification. Symp-
tom overlap is huge in psychiatry, and differences
between conditions are more quantitative than qualita-
tive. This is one of the reasons why dimensional
approachesmay be much more valid, albeit less practical,
than categorical. The problems of a categorical classifi-
cation in a dimensional world are as follows: (1) many
patientsdonotfitinanycategory(duetoartificialbound-
aries and ‘‘holes’’ between them); (2) many patients do
not achieve enough severity or duration of symptoms
to qualify for the full picture, despite suffering from sim-
ilarconsequencesasthosewiththewholesyndrome(spec-
trum);and (3) many patients fulfill criteria for several
conditions because of symptom overlap (comorbidity).
The only way that DSM-IV, ICD-10, and similar systems
have found to cope with problems related to discriminant
validity as those mentioned above has been to allow
for switching within categories (ie, unipolar to bipolar
after a manic episode) to include broad categories as
‘‘not otherwise specified,’’ the inclusion of milder catego-
ries within a spectrum (ie, bipolar II), and to allow for co-
existence of several diagnosis within the same patient
(comorbidity). However, and challenging the statement
that these classifications are atheoretical, some particular
comorbidities are not allowed: for instance, the apparent
dilemma of allowing the co-occurrence of the 2 major
psychoses, schizophrenia and manic-depressive illness
in the same patient, is solved with the introduction of
another intermediate category, schizoaffective disorder,
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avoid the problem. Conversely, some patients may hap-
pentofulfillcriteriaforover10differentconditions,aphe-
nomenon that does not happen in any other medical
speciality.
Laboratory data have been disappointing with regards
to support boundaries between conditions; they seem to
behave as symptoms, with important overlap and poor
specificity. There are some emerging data from neuroi-
maging studies, though, pointing to bipolar-specific re-
gional neural functional abnormalities (reviewed in the
companion article to this article). Again, however, genet-
ics, neuropathology, neurophysiology, neuroimaging,
biochemical challenge tests, and neuropsychology, while
providingsomesupporttodiagnosticboundaries,areun-
able to work at present as diagnostic tests in clinical prac-
tice. But even if we are not there yet, the preliminary
inclusion of laboratory data to support to some extent
the validity of either categories or dimensions may carry
more benefits than problems. In the future, laboratory
findingsfromresearchstudiesthatappeartodiscriminate
betweengroupsinhighlyselectedandartificiallyenriched
research samples should be the focus of subsequent diag-
nostic research in an attempt to research whether such
laboratory findings may have diagnostic value, in terms
of a sufficiently elevated likelihood ratio, in routine clin-
ical practice settings. It would be useful to compile a list
of diagnostic likelihood ratios of these measures, taking
into account the setting, the base prevalence of the disor-
der to be diagnosed in that particular setting, and use
these to develop quantitative diagnostic algorithms and
decision trees in a new module in the DSM and ICD sys-
tems. This approach is further discussed at the end of this
article.
Temporal Stability of Bipolar Disorder: Assessing
Predictive Validity
Temporal stability may be invoked as a criterion for
assessing the validity of psychiatric diagnosis as far as
the category in question is supposed to be stable over
time. Diagnostic reliability may also influence predictive
validity, as poor reliability might hamper the theoretical
stability ofacertain diagnostic category.Follow-up stud-
iesarecrucialtoassesspredictivevalidity.Categoriesthat
include chronicity as part of their definition are more
likely to be temporally stable (ie, schizophrenia), whereas
others are unstable almost by definition (schizophreni-
form disorder). In bipolar disorder, bipolar I is more sta-
ble than bipolar II just because bipolar II may switch to
bipolar I, but not vice versa. The stability of bipolar dis-
order has generally been reported to be high, ranging
from 70% to 91%.
28–31
Certain situations that may be developed by patients
over time, but which may not be part of the core syn-
drome but rather a particular longitudinal pattern, are
included in current classifications as course specifiers.
For bipolar disorder, they include chronicity (with or
without full interepisode recovery), seasonality, and
rapid cycling. A further potential specifier for DSM-V
may be ‘‘predominant polarity.’’ As many as 56% bipolar
patients display a specific pattern of predominant polar-
ity; 60% of those may be classified as predominantly de-
pressed (with at least two-thirds of past episodes fulfilling
criteria for major depression), whereas 40% may be clas-
sified as predominantly manic or hypomanic.
32 Table 1
shows the characteristics of the 2 groups.
A Proposal for DSM-V and ICD-11
Overcoming the Categorical Versus Dimensional
Approach Dilemma
The only way to overcome the problems associated to ei-
ther the categorical or the dimensional approach is to
adopt both. As discussed above, the dimensional ap-
proach may be closer to reality but may carry reliability
problemsandbedifficulttoimplementinreallife,includ-
ing aspects with important financial and social implica-
tions such as reimbursement policies, insurance issues,
and drug regulations; on the other hand, the categorical
approach has proved to be unsatisfactory with regards to
diagnostic validity and has carried problems such as
inflated comorbidity rates and a growing number of di-
agnostic categories (psychiatry is probably the only med-
ical speciality where the number of conditions is
continuously increasing rather than decreasing); how-
ever, the categorical approach is practical, easy, and re-
liable. We believe that switching from a categorical to
a dimensional classification would be unfeasible and ex-
tremely confusing, but we also think that the time has
come to include some dimensional information into
thesystem.Withthisregard,weproposethedevelopment
of a dimensional module within the categorical classifica-
tion that may end up to be extremely helpful for research,
teaching, and clinical practice, by allowing to assess in
a systematic way a limited number of issues, as listed
in table 2. These dimensions have been thought to
workforthemajorityofmentaldisorders,notjustbipolar
disorder. Patients would eventually be rated according
Table 1. Predominant Polarity Correlates
Depressive Polarity Manic Polarity
60% bipolar patients 40% bipolar patients
More bipolar II More bipolar I
More depressive onset More manic onset
More seasonal pattern Younger and earlier onset
More suicide attempts More substance misuse
Better long-term response to
lamotrigine
Better long-term response to
atypical antipsychotics
More antidepressant use
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moderate, or severe intensity or whether is absent at
all.Ofcourse,everydimensionshouldbeverywelldefined
a priori, and high scores in any dimension would deserve
further specifications in every case, but this would be
a simple way to start to develop a complementary dimen-
sional view over our rigid and poorly valid taxonomy.
Reﬁning Current Diagnostic Criteria
As mentioned, we do not want the categorical classifica-
tion to disappear. In fact, the dimensional module would
be a poor contribution if we were not able to refine, at the
same time, the current nosology. Refinements should be
data-driven. Further research is needed to assess the
sensitivity and specificity of diagnostic criteria and cat-
egories. Some of the specific problems related to the
diagnosis of bipolar disorder and issues that require
urgent revision are listed in table 3.
The Modular Approach
Themodularapproachaimstobeastepforwardtheaxial
approach, which proved successful in DSM-III but has
become partially obsolete. The modular approach
includes a first module which basically corresponds to
a refined axis I in current classification but also includes
some of the categories included in axis II, as certain con-
ditions controversially classified as personality disorders
(ie, borderline disorder); module I is the clinical diagnos-
tic classification, in which some hierarchical issues (pri-
mary vs secondary, etc) may or may not be included.
Module II involves the dimensional approach and
includes a limited number of potential symptomatic
dimensions (see table 2, for a preliminary proposal),
which can be dimensionally rated regardless of the diag-
nostic category according to module I. Module III is the
laboratory module and should include all the items in the
psychiatric toolbox (genotypation, structural and func-
tional neuroimaging, REM latency, hormonal tests, cog-
nitivedata)thatwouldenhancediagnosticvalidity.Inthe
companion article to this article, we therefore discuss fur-
ther the extent to which findings from recent structural
and functional neuroimaging studies in particular might
have increased our ability to identify potential bio-
markers of bipolar disorder to indeed enhance the diag-
nostic validity of the disorder. The modular approach
allows for a simple clinical diagnosis when such tools
are not available or not cost effective but permits to in-
tegrate the biological data as well when appropriate and
is the first step toward a future classification based on
pathophysiological grounds. Module IV corresponds to
axis III in DSMs and probably requires further attention,
especially for some nonpsychiatric conditions that are
overrepresented in the mentally ill and are likely to influ-
ence and to be influenced by the psychiatric disorder (ie,
diabetes, obesity, cancer, cardiovascular disease, etc).
The medical morbidity in bipolar disorder is extremely
high and rapidly increasing.
33 Module V should be the
psychologicalmodule andshouldincludeall the informa-
tion about personality and usual behavior of the subject
that may be relevant for psychiatric assessment. Some,
but not all, of the items and categories currently included
Table2. Aproposalfordimensionalclassificationasafurtheraxis
or module for the classification of mental disorders
Dimension/Severity
None
(absent) Mild Moderate Severe
Psychotic (positive)
symptoms
01 2 3
Negative symptoms 0 1 2 3
Manic symptoms 0 1 2 3
Depressive symptoms 0 1 2 3
Cognitive impairment 0 1 2 3
Anxiety 0 1 2 3
Obsessive-compulsive
symptoms
01 2 3
Substance misuse 0 1 2 3
Impulsivity 0 1 2 3
Suicidality 0 1 2 3
Eating problems 0 1 2 3
Sleeping problems 0 1 2 3
Sexual problems 0 1 2 3
Table 3. Limitations of Current Diagnostic Criteria for Bipolar
Disorder
  Psychotic symptoms are common in mania and may also
happen in depression, but they are not part of the diagnostic
criteria, reinforcing the idea that psychosis is a core feature of
schizophrenia but not bipolar disorder
  Mood-congruent vs mood-incongruent psychotic symptoms are
not well defined
  Bipolar depression is undistinguishable from unipolar major
depression
  Recurring depressions are not recognized as a potential
precursor to bipolar disorder—may be diagnosed as
a depressive disorder
  Mixed symptoms are not sufficiently characterized, and mixed
episodes are too narrowly defined
  Cognitive symptoms are not included
  Drug-induced mania and hypomania are excluded: problems in
judging what ‘‘direct physiological consequence of a drug,
medication, or somatic treatment’’ means
  No account is taken of family history and biological markers
  Four-day duration required for diagnosis of hypomania and 1
week for mania may be too long
  Bipolar disorder not-otherwise-specified may include the
majority of cases, particularly in children and adolescents
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essarily haveadimensionalformat, avoidingall the prob-
lems related to poor validity and reliability of personality
disorders as described in DSM-IV and ICD-10. Finally,
the social issues should be assessed in module VI, includ-
ing what is currently included in axis IV and V of DSM-
IV, namely psychosocial and environmental problems
and social functioning. A summary of the modular ap-
proach is shown in table 4.
In conclusion, the validity of psychiatric diagnosis in
general and bipolar disorder in particular deserves fur-
ther research and alternative approaches. There is a clear
need to improve and refine the current diagnostic criteria
and to introduce dimensions not as an alternative but
rather as a useful complement to categorical diagnosis.
Laboratory, family, and treatment response data should
also be systematically included in the diagnostic assess-
ment when available. There is little chance that DSM-
V or ICD-11 may represent a true step forward if these
kinds of data are not included. We propose a modular
system that may integrate categorical and dimensional
issues, laboratory data, associated nonpsychiatric med-
ical conditions, psychological assessment, and social
issues in a comprehensive and nevertheless practical
approach.
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